MedTrace Logo

NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy

NCT00535275 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2015-02-16

No results posted yet for this study

Summary

Relapses after perioperative chemotherapy and surgery

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Chemotherapy with platine

Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)

DRUG

Chemotherapy without Cisplatine

Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)

Sponsors & Collaborators

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Denis Moro-Sibilot, Pr · University Hospital, Grenoble

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00535275 on ClinicalTrials.gov